Application of cryptotanshinone in preparation of angiogenesis promoting agent under normal oxygen condition
The invention discloses application of cryptotanshinone in preparation of an angiogenesis promoting agent under a normal oxygen condition, and belongs to the technical field of medicines. The invention shows that the cryptotanshinone (CTS) can obviously up-regulate the expression of hypoxia-inducible factors (HIF-1alpha) of four cells, namely human lung normal fibroblasts (MRC-5), human umbilical vein cells (EA.hy926), glioma cells (U251) and human soft osteosarcoma cells (SW1353) and target gene vascular endothelial cell growth factors (VEGF) of the hypoxia-inducible factors (HIF-1alpha) under normal oxygen, and the effect is cell type dependence; meanwhile, the CTS inhibits phosphorylation of PHD2 protein by promoting secretion and/or expression of JNK and P38 protein, so that hydroxylation and degradation of HIF-1alpha are avoided. Therefore, the invention provides the effect of cryptotanshinone in promoting the revascularization, especially in promoting the microvascular regeneration under the normal oxygen condition, and the cryptotanshinone can be used for effectively preparing the medicine for treating ischemic vascular diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 06. Sept. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
TENG HUAJIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-09-06, Last update posted on www.tib.eu: 2023-06-21, Last updated: 2023-06-30 |
|---|
| Patentnummer: |
CN115006409 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017350514 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017350514 | ||
| 003 | DE-627 | ||
| 005 | 20230630124212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230623s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017350514 | ||
| 035 | |a (EPA)CN115006409 | ||
| 035 | |a (EPA)83080263 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a TENG HUAJIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of cryptotanshinone in preparation of angiogenesis promoting agent under normal oxygen condition |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-09-06, Last update posted on www.tib.eu: 2023-06-21, Last updated: 2023-06-30 | ||
| 520 | |a The invention discloses application of cryptotanshinone in preparation of an angiogenesis promoting agent under a normal oxygen condition, and belongs to the technical field of medicines. The invention shows that the cryptotanshinone (CTS) can obviously up-regulate the expression of hypoxia-inducible factors (HIF-1alpha) of four cells, namely human lung normal fibroblasts (MRC-5), human umbilical vein cells (EA.hy926), glioma cells (U251) and human soft osteosarcoma cells (SW1353) and target gene vascular endothelial cell growth factors (VEGF) of the hypoxia-inducible factors (HIF-1alpha) under normal oxygen, and the effect is cell type dependence; meanwhile, the CTS inhibits phosphorylation of PHD2 protein by promoting secretion and/or expression of JNK and P38 protein, so that hydroxylation and degradation of HIF-1alpha are avoided. Therefore, the invention provides the effect of cryptotanshinone in promoting the revascularization, especially in promoting the microvascular regeneration under the normal oxygen condition, and the cryptotanshinone can be used for effectively preparing the medicine for treating ischemic vascular diseases. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a JIANG QING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 06. Sept. |
| 773 | 1 | 8 | |g year:2022 |g day:06 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83080263/publication/CN115006409A1?q=CN115006409 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 06 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 06 |c 09 | ||